1. Home
  2. DSP vs ATAI Comparison

DSP vs ATAI Comparison

Compare DSP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

N/A

Current Price

$11.66

Market Cap

184.3M

Sector

Technology

ML Signal

N/A

ATAI

ATAI Life Sciences N.V.

N/A

Current Price

$4.09

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSP
ATAI
Founded
1999
2018
Country
United States
Netherlands
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.3M
1.4B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DSP
ATAI
Price
$11.66
$4.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$18.50
$14.00
AVG Volume (30 Days)
246.6K
3.2M
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
29.49
N/A
EPS
0.10
N/A
Revenue
$324,131,000.00
$3,018,000.00
Revenue This Year
$17.79
$943.83
Revenue Next Year
$17.72
N/A
P/E Ratio
$119.83
N/A
Revenue Growth
22.97
811.78
52 Week Low
$8.11
$1.15
52 Week High
$26.33
$6.75

Technical Indicators

Market Signals
Indicator
DSP
ATAI
Relative Strength Index (RSI) 61.78 43.27
Support Level $11.10 $4.25
Resistance Level $12.48 $4.63
Average True Range (ATR) 0.54 0.23
MACD -0.01 0.05
Stochastic Oscillator 59.57 39.74

Price Performance

Historical Comparison
DSP
ATAI

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About ATAI ATAI Life Sciences N.V.

Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.

Share on Social Networks: